Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rare Disease Cures Accelerator Expected To Drive Lots Of Development – Eventually

Executive Summary

You may also be interested in...



Complex Generics: Pre-Competitive Research Collaborations To Get US FDA Funding Boost

Center for Research on Complex Generics will be similar to the Critical Path Institute; training sessions for industry could begin in January.

Rare Diseases And Beyond: FDA Seeks Input On Establishing Clinical Trial Networks

US FDA is looking for advice on how to design a clinical trial network to complete the third component of its Rare Disease Cures Accelerator Program, but it also wants advice on clinical trial networks more broadly. The rare disease network will need to be global given the more limited patient populations, the agency said.

US FDA Wins Big In Shutdown-Averting Approps Bill

Agency would receive more than $268m in additional dollars for medical product and food safety as part of substantial FY 2019 increase.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS140857

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel